These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 34871447)
1. A case of sensory ataxic Guillain-Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer). Fukushima T; Tomita M; Ikeda S; Hattori N QJM; 2022 Jan; 115(1):25-27. PubMed ID: 34871447 [No Abstract] [Full Text] [Related]
2. Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination. Ogata S; Ishii Y; Asano K; Kobayashi E; Kubota S; Takahashi K; Miyaji Y; Higashiyama Y; Joki H; Doi H; Koga M; Takeuchi H; Tanaka F Intern Med; 2022 Jun; 61(11):1757-1760. PubMed ID: 35342134 [TBL] [Abstract][Full Text] [Related]
4. Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine. Trimboli M; Zoleo P; Arabia G; Gambardella A Neurol Sci; 2021 Nov; 42(11):4401-4402. PubMed ID: 34346014 [No Abstract] [Full Text] [Related]
5. Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases. Bouattour N; Hdiji O; Sakka S; Fakhfakh E; Moalla K; Daoud S; Farhat N; Damak M; Mhiri C Neurol Sci; 2022 Feb; 43(2):755-761. PubMed ID: 34796417 [TBL] [Abstract][Full Text] [Related]
6. Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay. Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi GL; Lippi G Clin Chem Lab Med; 2021 Sep; 59(10):e377-e379. PubMed ID: 34162025 [No Abstract] [Full Text] [Related]
7. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months. Ponticelli D; Antonazzo IC; Caci G; Vitale A; Della Ragione G; Romano ML; Borrelli M; Schiavone B; Polosa R; Ferrara P J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34697627 [No Abstract] [Full Text] [Related]
8. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
9. Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent. Malamud E; Otallah SI; Caress JB; Lapid DJ Pediatr Neurol; 2022 Jan; 126():9-10. PubMed ID: 34717201 [No Abstract] [Full Text] [Related]
10. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
11. Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine. Scendoni R; Petrelli C; Scaloni G; Logullo FO Hum Vaccin Immunother; 2021 Nov; 17(11):4093-4096. PubMed ID: 34347563 [TBL] [Abstract][Full Text] [Related]
12. [A Patient Developing Guillain-Barré Syndrome After Receiving the BNT162b2 COVID-19 mRNA Vaccine]. Oshibe N; Honda M; Koga M; Sato R; Oishi M; Kanda T Brain Nerve; 2022 Aug; 74(8):1025-1030. PubMed ID: 35941801 [TBL] [Abstract][Full Text] [Related]
13. Guillain-Barré syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea. Kim N; Kim JH; Park JS Neurol Sci; 2022 Mar; 43(3):1491-1493. PubMed ID: 34981285 [No Abstract] [Full Text] [Related]
14. Viral-like Reaction or Hypersensitivity? Erythema Multiforme Minor Reaction and Moderate Eosinophilia After the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 Vaccine. de Las Vecillas L; López J; Morchón E; Rodriguez F; Drake M; Martino M J Investig Allergol Clin Immunol; 2021 Feb; 32(1):77-78. PubMed ID: 34588156 [No Abstract] [Full Text] [Related]
16. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. García-Grimshaw M; Michel-Chávez A; Vera-Zertuche JM; Galnares-Olalde JA; Hernández-Vanegas LE; Figueroa-Cucurachi M; Paredes-Ceballos O; Reyes-Terán G; Carbajal-Sandoval G; Ceballos-Liceaga SE; Arauz A; Valdés-Ferrer SI Clin Immunol; 2021 Sep; 230():108818. PubMed ID: 34358692 [TBL] [Abstract][Full Text] [Related]
17. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review. Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB Front Public Health; 2021; 9():778964. PubMed ID: 34888290 [No Abstract] [Full Text] [Related]
18. Guillain-Barré Syndrome in an Australian State Using Both mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines. Osowicki J; Morgan H; Harris A; Crawford NW; Buttery JP; Kiers L Ann Neurol; 2021 Nov; 90(5):856-858. PubMed ID: 34528279 [No Abstract] [Full Text] [Related]